BioCentury
ARTICLE | Company News

AbbVie discounts Viekira Pak for ADAPs

January 21, 2015 4:58 AM UTC

AbbVie Inc. (NYSE:ABBV) entered an agreement with the ADAP Crisis Task Force (ACTF) to provide its HCV regimen Viekira Pak at an undisclosed discount to state AIDS Drug Assistance Programs (ADAPs).

In December, FDA approved Viekira Pak with or without ribavirin to treat HCV genotype 1 infection in patients with and without compensated cirrhosis, including those co-infected with HIV. AbbVie set the WAC for the three direct-acting-antiviral (3-DAA) treatment regimen at $83,319 for a 12-week course (see BioCentury Extra, Dec. 19, 2014). ...